At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 170 enrolled
Drug / intervention
Epoetin betadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Randomized, Multi-centre Trial to Investigate the Effect of Anemia Correction on Cardiac Structure and Function in Patients With Early Diabetic Nephropathy
In Brief
A Phase 3 clinical trial evaluating Epoetin beta for Anemia. Completed, enrolled 170 participants across 63 sites in 17 countries.
Detailed Summary
This study will assess the effect of anemia correction with NeoRecormon on cardiac structure and function in patients with early diabetic nephropathy. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesAustria, Brazil, Czechia, Denmark, Finland, Germany, Greece, Hungary, Italy, Mexico, Poland, Russia, Singapore, Spain, Sweden, Thailand, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2002
Primary CompletionJul 2005
First PostedJul 2006
TodayJul 2026
First PostedJul 20, 2006
Enrollment StartSep 1, 2002
Primary CompletionJul 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.9 years ago
Interventions
Epoetin betadrug